{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039795","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.618064+00:00","generated_at":"2026-06-12T02:07:35.918637+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Treace Medical Q2 revenue $42M (+40% YoY); raises FY guidance to $191-197M","bullets":["Revenue $42.0M, up 40% YoY; gross margin 81.7% vs 82.3% last year.","Net loss per share ($0.20) improved from ($0.31) YoY; adjusted EBITDA loss ($7.7M).","FY2023 revenue guidance raised to $191-197M, representing 35-39% growth.","Direct sales channel grew to 79% of sales; reached 200 quota-carrying sales reps.","Completed acquisition of RedPoint Medical3D assets for patient-specific instrumentation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039795","json":"https://secwatch.observer/filing/0000950170-23-039795.json","markdown":"https://secwatch.observer/filing/0000950170-23-039795.md","text":"https://secwatch.observer/filing/0000950170-23-039795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000095017023039795/0000950170-23-039795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000095017023039795/tmci-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:07:35.918637+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4241612d4001faffb2a56ef1a2cd1f898ddf4ad1","claim":"TREACE MEDICAL CONCEPTS, INC. reported quarter ended June 30, 2023 results: net income Second quarter net loss attributable to common stockholders was ($12.3) million, EPS ($0.20) per share. Guidance raised.","evidence_excerpt":"Revenue of $42.0 million in the second quarter of 2023, a 40% increase over same period last year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630627/000095017023039795/0000950170-23-039795-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Net income","value":"Second quarter net loss attributable to common stockholders was ($12.3) million"},{"label":"EPS","value":"($0.20) per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4241612d4001faffb2a56ef1a2cd1f898ddf4ad1","claim":"TREACE MEDICAL CONCEPTS, INC. reported quarter ended June 30, 2023 results: net income Second quarter net loss attributable to common stockholders was ($12.3) million, EPS ($0.20) per share. Guidance raised.","evidence_excerpt":"Second quarter net loss attributable to common stockholders was ($12.3) million, or ($0.20) per share, compared to ($17.2) million, or ($0.31) per share, for the same period of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630627/000095017023039795/0000950170-23-039795-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Net income","value":"Second quarter net loss attributable to common stockholders was ($12.3) million"},{"label":"EPS","value":"($0.20) per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9c7aee78fcc93ec7a13dd7803a527e7ea6e26bd2","claim":"TREACE MEDICAL CONCEPTS, INC. reported full-year 2023 results: revenue $191 million to $197 million. Guidance raised.","evidence_excerpt":"Treace is raising its full-year 2023 revenue guidance to $191 million to $197 million, which represents approximately 35% to 39% growth over the Company’s 2022 revenue.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630627/000095017023039795/0000950170-23-039795-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"Revenue","value":"$191 million to $197 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}